149 related articles for article (PubMed ID: 38259447)
21. Clinical and laboratory features of fatal rapidly progressive interstitial lung disease associated with juvenile dermatomyositis.
Kobayashi N; Takezaki S; Kobayashi I; Iwata N; Mori M; Nagai K; Nakano N; Miyoshi M; Kinjo N; Murata T; Masunaga K; Umebayashi H; Imagawa T; Agematsu K; Sato S; Kuwana M; Yamada M; Takei S; Yokota S; Koike K; Ariga T
Rheumatology (Oxford); 2015 May; 54(5):784-91. PubMed ID: 25288783
[TBL] [Abstract][Full Text] [Related]
22. Myocardial involvement is not rare in anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis/clinically amyopathic dermatomyositis: a retrospective study.
Zhou S; Lai J; Wu C; Liu Y; Liu Y; Zhao J; Xu D; Tian X; Li M; Zhao Y; Wang Y; Wang Q; Zeng X
Front Immunol; 2022; 13():928861. PubMed ID: 35983058
[TBL] [Abstract][Full Text] [Related]
23. Prognostic values of anti-Ro52 antibodies in anti-MDA5-positive clinically amyopathic dermatomyositis associated with interstitial lung disease.
Xu A; Ye Y; Fu Q; Lian X; Chen S; Guo Q; Lu LJ; Dai M; Lv X; Bao C
Rheumatology (Oxford); 2021 Jul; 60(7):3343-3351. PubMed ID: 33331866
[TBL] [Abstract][Full Text] [Related]
24. Antimelanoma differentiation-associated protein 5 antibody level is a novel tool for monitoring disease activity in rapidly progressive interstitial lung disease with dermatomyositis.
Matsushita T; Mizumaki K; Kano M; Yagi N; Tennichi M; Takeuchi A; Okamoto Y; Hamaguchi Y; Murakami A; Hasegawa M; Kuwana M; Fujimoto M; Takehara K
Br J Dermatol; 2017 Feb; 176(2):395-402. PubMed ID: 27452897
[TBL] [Abstract][Full Text] [Related]
25. Clinical Heterogeneity of Interstitial Lung Disease in Polymyositis and Dermatomyositis Patients With or Without Specific Autoantibodies.
Chen F; Li S; Wang T; Shi J; Wang G
Am J Med Sci; 2018 Jan; 355(1):48-53. PubMed ID: 29289262
[TBL] [Abstract][Full Text] [Related]
26. Comprehensive assessment of myositis-specific autoantibodies in polymyositis/dermatomyositis-associated interstitial lung disease.
Hozumi H; Fujisawa T; Nakashima R; Johkoh T; Sumikawa H; Murakami A; Enomoto N; Inui N; Nakamura Y; Hosono Y; Imura Y; Mimori T; Suda T
Respir Med; 2016 Dec; 121():91-99. PubMed ID: 27888997
[TBL] [Abstract][Full Text] [Related]
27. Initial predictors for short-term prognosis in anti-melanoma differentiation-associated protein-5 positive patients.
Yang Q; Li T; Zhang X; Lyu K; Wu S; Chen Y; Liu S; Yu Z
Orphanet J Rare Dis; 2021 Jan; 16(1):58. PubMed ID: 33516242
[TBL] [Abstract][Full Text] [Related]
28. Quantitative CT analysis of interstitial pneumonia in anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis: a single center, retrospective study.
Yamaguchi K; Nakajima T; Yamaguchi A; Itai M; Onuki Y; Shin Y; Uno S; Muto S; Kouno S; Yatomi M; Aoki-Saito H; Hara K; Endo Y; Motegi SI; Muro Y; Nakasatomi M; Sakairi T; Hiromura K; Katsumata N; Hirasawa H; Tsushima Y; Maeno T
Clin Rheumatol; 2022 May; 41(5):1473-1481. PubMed ID: 35034225
[TBL] [Abstract][Full Text] [Related]
29. Roles of biomarkers in anti-MDA5-positive dermatomyositis, associated interstitial lung disease, and rapidly progressive interstitial lung disease.
Li X; Liu Y; Cheng L; Huang Y; Yan S; Li H; Zhan H; Li Y
J Clin Lab Anal; 2022 Nov; 36(11):e24726. PubMed ID: 36221983
[TBL] [Abstract][Full Text] [Related]
30. Rituximab in the Treatment of Interstitial Lung Diseases Related to Anti-Melanoma Differentiation-Associated Gene 5 Dermatomyositis: A Systematic Review.
He C; Li W; Xie Q; Yin G
Front Immunol; 2021; 12():820163. PubMed ID: 35116041
[TBL] [Abstract][Full Text] [Related]
31. Interstitial Lung Disease with Anti-melanoma Differentiation-associated Protein 5 Antibody: Rapidly Progressive Perilobular Opacity.
Chino H; Sekine A; Baba T; Kitamura H; Iwasawa T; Okudela K; Takemura T; Itoh H; Sato S; Suzuki Y; Ogura T
Intern Med; 2019 Sep; 58(18):2605-2613. PubMed ID: 31178482
[TBL] [Abstract][Full Text] [Related]
32. Serum YKL-40 level is associated with severity of interstitial lung disease and poor prognosis in dermatomyositis with anti-MDA5 antibody.
Jiang L; Wang Y; Peng Q; Shu X; Wang G; Wu X
Clin Rheumatol; 2019 Jun; 38(6):1655-1663. PubMed ID: 30739212
[TBL] [Abstract][Full Text] [Related]
33. Fatal outcome of anti-MDA5 juvenile dermatomyositis in a paediatric COVID-19 patient: a case report.
Quintana-Ortega C; Remesal A; Ruiz de Valbuena M; de la Serna O; Laplaza-González M; Álvarez-Rojas E; Udaondo C; Alcobendas R; Murias S
Mod Rheumatol Case Rep; 2021 Jan; 5(1):101-107. PubMed ID: 33019894
[TBL] [Abstract][Full Text] [Related]
34. Characteristics and prognostic implications of peripheral blood lymphocyte subsets in patients with anti-MDA5 antibody positive dermatomyositis-interstitial lung disease.
Ren FP; Chen Q; Yao SS; Feng L; Xue XY; Zhao WC; Wang D; Zhao ZL; Gu SW; Li T; Shen YW; Gao L; Zang XL; Bao XY; Tong ZH
BMC Pulm Med; 2023 Oct; 23(1):411. PubMed ID: 37898737
[TBL] [Abstract][Full Text] [Related]
35. Progranulin correlated with rapid progressive interstitial lung disease in dermatomyositis with anti-melanoma differentiation-associated gene 5 antibody.
Shanshan L; Yamei Z; Ling Z; Xin L; Guochun W
Clin Rheumatol; 2022 Mar; 41(3):757-763. PubMed ID: 34718893
[TBL] [Abstract][Full Text] [Related]
36. Differential clinical features of patients with clinically amyopathic dermatomyositis who have circulating anti-MDA5 autoantibodies with or without myositis-associated autoantibodies.
Yamaguchi K; Yamaguchi A; Kashiwagi C; Sawada Y; Taguchi K; Umetsu K; Oshima K; Uchida M; Suzuki M; Kono S; Takemura M; Masubuchi H; Kitahara S; Hara K; Maeno T; Motegi SI; Muro Y; Sakairi T; Hisada T; Kurabayashi M
Respir Med; 2018 Jul; 140():1-5. PubMed ID: 29957268
[TBL] [Abstract][Full Text] [Related]
37. Risk factors for mortality in patients with anti-MDA5 antibody-positive dermatomyositis: A meta-analysis and systematic review.
Xie H; Zhang D; Wang Y; Shi Y; Yuan Y; Wang L; Fan J; Tian X; Wang J
Semin Arthritis Rheum; 2023 Oct; 62():152231. PubMed ID: 37348186
[TBL] [Abstract][Full Text] [Related]
38. Increased Serum B Cell Activating Factor and a Proliferation-inducing Ligand Are Associated with Interstitial Lung Disease in Patients with Juvenile Dermatomyositis.
Kobayashi N; Kobayashi I; Mori M; Sato S; Iwata N; Shigemura T; Agematsu K; Yokota S; Koike K
J Rheumatol; 2015 Dec; 42(12):2412-8. PubMed ID: 26472413
[TBL] [Abstract][Full Text] [Related]
39. Forced vital capacity predicts the survival of interstitial lung disease in anti-MDA5 positive dermatomyositis: a multi-centre cohort study.
Wu W; Xu W; Sun W; Zhang D; Zhao J; Luo Q; Wang X; Zhu F; Zheng Y; Xue Y; Wan W; Wu H; Han Q; Ye S
Rheumatology (Oxford); 2021 Dec; 61(1):230-239. PubMed ID: 33764398
[TBL] [Abstract][Full Text] [Related]
40. Successful treatment of anti-MDA5 antibody-positive refractory interstitial lung disease with plasma exchange therapy.
Abe Y; Kusaoi M; Tada K; Yamaji K; Tamura N
Rheumatology (Oxford); 2020 Apr; 59(4):767-771. PubMed ID: 31504956
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
